1. 2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts). (September 2015) Authors: Shore, N.; Bailen, J.; Pieczonka, C.; MacLean, D.; Shi, H.; Faessel, H.; Saad, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer. (September 2015) Authors: Petrylak, D.; Quinn, D.; Dreicer, R.; Antonarakis, E.; Shore, N.; Corman, J.; Concepcion, R.; Pieczonka, C.; Chang, N.; DeVries, T.; Sheikh, N.; Drake, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗